A trial of CT-P59, an anti-COVID-19 monoclonal antibody, has completed its enrolment and will study the treatment against standard-of-care.
List view / Grid view
Korean Ministry of Food and Drug Safety (MFDS)
Filter the results
Celltrion Group's CT-P59 antibody will be tested as a COVID-19 prophylactic in a Phase III clinical trial.